Polar Asset Management Partners Inc. Acquires 302,112 Shares of Edwards Lifesciences Co. (NYSE:EW)

Polar Asset Management Partners Inc. increased its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 342.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 390,312 shares of the medical research company's stock after purchasing an additional 302,112 shares during the quarter. Polar Asset Management Partners Inc. owned approximately 0.07% of Edwards Lifesciences worth $28,895,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Norges Bank purchased a new position in Edwards Lifesciences in the fourth quarter valued at about $610,895,000. Jennison Associates LLC purchased a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $555,939,000. Vanguard Group Inc. increased its position in shares of Edwards Lifesciences by 10.4% during the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock worth $5,117,845,000 after purchasing an additional 6,537,494 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Edwards Lifesciences during the fourth quarter worth $213,844,000. Finally, Marshall Wace LLP boosted its holdings in Edwards Lifesciences by 55.7% in the fourth quarter. Marshall Wace LLP now owns 5,813,419 shares of the medical research company's stock worth $430,367,000 after acquiring an additional 2,079,642 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In related news, VP Daveen Chopra sold 1,500 shares of the business's stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total transaction of $112,620.00. Following the transaction, the vice president now directly owns 33,496 shares of the company's stock, valued at approximately $2,514,879.68. The trade was a 4.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 400 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the sale, the vice president now directly owns 22,588 shares of the company's stock, valued at $1,569,414.24. This represents a 1.74% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 56,442 shares of company stock worth $4,025,799 in the last ninety days. Insiders own 0.34% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Truist Financial dropped their price objective on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Barclays raised their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. Evercore ISI lowered their price target on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a report on Wednesday, February 12th. Piper Sandler boosted their price objective on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a report on Tuesday, May 13th. Finally, Morgan Stanley boosted their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $80.20.

Edwards Lifesciences Stock Performance

Shares of EW traded up $0.13 during mid-day trading on Friday, hitting $77.86. The company's stock had a trading volume of 3,133,067 shares, compared to its average volume of 5,160,049. The stock's 50-day moving average is $73.22 and its two-hundred day moving average is $72.33. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market capitalization of $45.67 billion, a PE ratio of 11.17, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. During the same period last year, the company earned $0.66 earnings per share. Edwards Lifesciences's quarterly revenue was up 6.2% on a year-over-year basis. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.